Correlation Between Appropriateness Prescribing Antibiotics and Clinical Improvement on Hospitalized Patients with Community Acquired Pneumonia Based on The Gyssens Method

  • Cut Fatia Ulfa Fakultas Farmasi, Universitas Ahmad Dahlan
  • Woro Supadmi Fakultas Farmasi, Universitas Ahmad Dahlan
  • Dyah Aryani Perwitasari Fakultas Farmasi, Universitas Ahmad Dahlan
  • Endang Yuniarti Fakultas Farmasi, Stikes Muhammadiyah Gombong
DOI: https://doi.org/10.35814/jifi.v19i1.940

Abstract

Community-acquired pneumonia is an acute inflammation of the pulmonary parenchyma caused by bacterial infection. . The main therapy for community-acquired pneumonia is the use of antibiotics. Inappropriate antibiotics can lead to bacterial resistance. The study aims to determine Appropriateness of antibiotics prescribing using the method Gyssens with clinical improvement. This study is a retrospective analytic cohort descriptive. Data was collected retrospectively based on medical records of inpatients at one of the hospital in Yogyakarta for the January-December 2019 period based. The accuracy of empiric antibiotic prescription using the Gyssens method. The clinical improvements observed were leukocyte count, temperature, respiratory rate. This study was analyzed using the chi square method. The results showed 41 patients met the inclusion and exclusion criteria, male gender (51.2%), age> 60 years 68.3%, the average length of stay was five days. Ceftriaksone is a commonly used antibiotic. Evaluation prescribing appropriateness based on the Gyssens method of 52 antibiotic regimens. appropriate antibiotic prescribing (13.5%) and inappropriate (86.5%). The correlation between appropriateness of antibiotics prescribing with clinical improvement leukocytes count, respiratory rate and temperature did not significant (p> 0.05). There was no correlation between the accurasy of antibiotics prescribing based on the Gyssens method with clinical improvement.

References

1. PDPI. Pneumonia komunitas pedoman diagnosis & penatalaksanaan di Indonesia (2nd ed.). Badan Penerbit FKUI. 2014.

2. World Health Organization. 2016;Top 10 Causes of death. Diambil dari: https://www.who.int/en/news- room/fact-sheets/detail/the-top-10-causes-of-death. diakses 1 maret 2020.

3. Arnold FW, Wiemken TL, Peyrani P, Ramirez JA, & Brock GN. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the community-acquired pneumonia organization (CAPO) International Cohort Study. Respiratory Medicine. 2013. 107(7). 1101–1111.

4. Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al. Adults hospitalized with pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clinical Infectious Diseases. 2017. 65(11):1806–1812.

5. Kemenkes RI. Profil kesehatan indonesia. 2018.

6. Kaysin A, Viera AJ. Community acquired pneumonia in adults: diagnosis and management. American Family Physician. 2016. 94(9): 698–706.

7. Farida H, Gasem MH, Suryanto A, Keuter M, Zulkarnain N, Satoto B, et al. Viruses and gram- negative bacilli dominate the etiology of community- acquired pneumonia in Indonesia, a cohort study. International Journal of
Infectious Diseases. 2015. 38: 101–107.

8. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. American Journal of Respiratory and Critical Care Medicine. 2019. 200(7): 45–67.

9. Klompas M, Ochoa A, Ji W, McKenna C, Clark R, Shenoy ES, Hooper D, et al. Prevalence of clinical signs within reference ranges among hospitalized patients prescribed antibiotics for pneumonia. JAMA. 2020. 3(7):1–12.

10. Kemenkes. Program pengendalian resistensi antimikroba di rumah sakit. 2015 :1–31.

11. Oktovina MN. Alur Gyssen analisa kualitatif pada penggunaan antibiotik. Fatmawati Hospital Journal. 2015. 1–5.

12. Kemenkes RI. Pedoman umum penggunaan antibiotik. Pedoman umum penggunaan antibiotik. 2011:874:4.

13. Spivak ES, Cosgrove SE, & Srinivasan A. Measuring appropriate antimicrobial use: attempts at opening the black box. Infectious Diseases Society of America. 2016. 63(12):1639–1644.

14. Rahayu YD, Wahyono D, & Mustofa. Evaluasi rasionalitas penggunaan antibiotik terhadap luaran pada pasien anak penderita pneumonia. Journal.Ugm. Ac.Id. 2014. 4(1):264–270.

15. Faisal F, Burhan E, Aniwidyaningsih W, Kekalih A. Penilaian respons pengobatan empiris pada pasien rawat inap dengan pneumonia komunitas. J Respir Indo. 2014. 34(2):60–70.

16. Nie XM, Li YS, Yang ZW, Wang H, Jin SY, Jiao Y, et al. Initial empiric antibiotic therapy for community- acquired pneumonia in Chinese hospitals. Clinical Microbiology and Infection. 2018. 24(6):1-6.

17. Sari EF, Rumende CM, & Harimurti K. Faktor-faktor yang berhubungan dengan diagnosis pneumonia pada pasien usia lanjut. Jurnal Penyakit Dalam Indonesia. 2017. 3(4):183.

18. Mulyana R. Terapi antibiotika pada pneumonia usia lanjut. Jurnal Kesehatan Andalas. 2019. 8(1):172–177.

19. Permenkes RI. Tentang penyelenggaraan pelayanan kesehatan lanjut usia di pusat kesehatan masyarakat. Kementrian Kesehatan Indonesia. 2015:1–140.

20. Eurich DT, Marrie TJ, Minhas-Sandhu JK, & Majumdar SR. Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-up. BMJ 2017. 356:1–9.

21. Sudibyo J. Kajian praktek penggantian antibiotika terapi intravena ke oral pada pasien pneumonia di rawat inap Rs Pku Muhammadiyah Gamping. Journal of Petrology. 2019.

22. Firmansyah MA, Amin Z, Loho T, & Shatri H. Faktor- faktor prediktor mortalitas community-acquired pneumonia dalam perawatan inap di rumah sakit Cipto Mangunkusumo, Jakarta. Ina J CHEST Crit and Emerg Med. 2015. 2(2):45–5.

23. Yulia R, Mariza JW, Soedarsono, & Herawati F. Bacterial profile and antibiotic use in pneumonia patients at Dr. Soetomo General Hospital. Current Respiratory Medicine Reviews. 2020. 16:1–7.

24. Islam, Zainul, Qodariyah SM, & Nursehah E. Penggunaan antibiotik pada terapi community acquired pneumonia di RSUD Pasar Rebo dan RSUD Tarakan di Jakarta tahun 2014. Jurnal Sains Dan Teknologi Farmasi. 2017. 19(01):1–8.

25. Postma DF, Van Werkhoven CH, Van Elden LJR, Thijsen SFT, Hoepelman AIM, Kluytmans JAJ, et al. Antibiotic treatment strategies for community- acquired pneumonia in adults. New England Journal of Medicine. 2015. 372(14):1312–1323.

26. Leyenaar JK, Shieh MS, Lagu T, Pekow PS, & Lindenauer PK. Comparative effectiveness of ceftriaxone in combination with a macrolide compared with ceftriaxone alone for pediatric patients hospitalized with community acquired pneumonia. Pediatr Infect Dis J. 2014. 33(4):387–392.

27. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases. 2007. 44:S27–S72.

28. Rumende CM, Chen LK, Karuniawat A, Bratanata J, Falasiva R, Sitorus TP, et al. Hubungan antara ketepatan pemberian antibiotik berdasarkan alur Gyssens dengan perbaikan klinis pasien pada pneumonia komunitas. Jurnal Penyakit Dalam Indonesia. 2019. 6(2):71-78.

29. Nurraya L, Maksum R, & Alfina R. Analisis perbandingan antara monoterapi dengan dualterapi
antibiotik extended empiric pada pasien community- acquired pneumonia di RSUP Fatmawati Jakarta. Jurnal Sains Farmasi & Klinis. 2019. 2(6):147–157.

30. Rusmini H. Gambaran penggunaan antibiotik pada pasien pneumonia dengan menggunakan metode Gyssens di rawat inap rumah sakit umum daerah (RSUD) H. Abdul Moeloek Tahun 2015. Jurnal Medika Malahayati. 2016. 3(2):61–64.

31. Cilli A, Sayiner A, Celenk B, Şakar CoSkun A, Kilinc O, et al (2018). Antibiotic treatment outcomes in community-acquired pneumonia. Turkish Journal of Medical Sciences.2018. 48(4):730-736.
Published
2021-04-21
How to Cite
ULFA, Cut Fatia et al. Correlation Between Appropriateness Prescribing Antibiotics and Clinical Improvement on Hospitalized Patients with Community Acquired Pneumonia Based on The Gyssens Method. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 19, n. 1, p. 30-38, apr. 2021. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/940>. Date accessed: 05 nov. 2024. doi: https://doi.org/10.35814/jifi.v19i1.940.
Citation Formats
Issue
Vol 19 No 1 (2021): JIFI
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.